Jefferies Group Comments on Aclaris Therapeutics Inc.’s FY2018 Earnings (ACRS)
Aclaris Therapeutics Inc. (NASDAQ:ACRS) – Jefferies Group lowered their FY2018 EPS estimates for Aclaris Therapeutics in a research report issued on Monday. Jefferies Group analyst D. Steinberg now anticipates that the firm will earn ($2.65) per share for the year, down from their previous forecast of ($2.33). Jefferies Group currently has a “Buy” rating and a $31.00 target price on the stock. Jefferies Group also issued estimates for Aclaris Therapeutics’ FY2019 earnings at $0.44 EPS and FY2020 earnings at $2.44 EPS.
A number of other brokerages have also recently issued reports on ACRS. Zacks Investment Research raised shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 23rd. Guggenheim assumed coverage on shares of Aclaris Therapeutics in a research report on Friday, June 10th. They set a “buy” rating and a $35.00 price target for the company. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. Aclaris Therapeutics currently has an average rating of “Buy” and a consensus price target of $31.25.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) traded up 0.49% on Wednesday, hitting $24.50. 207,339 shares of the stock were exchanged. The company has a 50-day moving average price of $21.05 and a 200 day moving average price of $19.69. Aclaris Therapeutics has a 12 month low of $10.99 and a 12 month high of $33.88. The company’s market cap is $524.67 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/jefferies-group-comments-on-aclaris-therapeutics-inc-s-fy2018-earnings-acrs.html
Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.01.
In other Aclaris Therapeutics news, major shareholder Ra Capital Management, Llc sold 525,550 shares of the company’s stock in a transaction on Friday, September 16th. The shares were sold at an average price of $24.19, for a total value of $12,713,054.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Kamil Ali-Jackson sold 3,738 shares of the company’s stock in a transaction on Friday, August 26th. The stock was sold at an average price of $20.35, for a total transaction of $76,068.30. Following the completion of the transaction, the insider now owns 20,289 shares of the company’s stock, valued at $412,881.15. The disclosure for this sale can be found here. Company insiders own 46.40% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. raised its position in shares of Aclaris Therapeutics by 40.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 23,715 shares of the company’s stock valued at $439,000 after buying an additional 6,852 shares during the period. Sabby Management LLC bought a new position in shares of Aclaris Therapeutics during the second quarter valued at approximately $292,000. Opaleye Management Inc. raised its position in shares of Aclaris Therapeutics by 122.2% in the second quarter. Opaleye Management Inc. now owns 40,000 shares of the company’s stock valued at $326,000 after buying an additional 22,000 shares during the period. State Street Corp raised its position in shares of Aclaris Therapeutics by 64.8% in the second quarter. State Street Corp now owns 120,010 shares of the company’s stock valued at $2,217,000 after buying an additional 47,179 shares during the period. Finally, Teachers Advisors Inc. raised its position in shares of Aclaris Therapeutics by 91.0% in the second quarter. Teachers Advisors Inc. now owns 14,212 shares of the company’s stock valued at $262,000 after buying an additional 6,772 shares during the period. Institutional investors and hedge funds own 71.39% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.